Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Mar 6;7(1):63. doi: 10.1186/s40425-019-0547-7.

2.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

3.
4.

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.

Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J.

Eur J Immunol. 1996 Feb;26(2):435-43.

PMID:
8617315
5.

According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.

Moreno-Cubero E, Subirá D, Sanz-de-Villalobos E, Parra-Cid T, Madejón A, Miquel J, Olveira A, González-Praetorius A, García-Samaniego J, Larrubia JR.

J Virol. 2018 Jan 2;92(2). pii: e01443-17. doi: 10.1128/JVI.01443-17. Print 2018 Jan 15.

6.

Bim-mediated apoptosis and PD-1/PD-L1 pathway impair reactivity of PD1(+)/CD127(-) HCV-specific CD8(+) cells targeting the virus in chronic hepatitis C virus infection.

Larrubia JR, Benito-Martínez S, Miquel J, Calvino M, Sanz-de-Villalobos E, González-Praetorius A, Albertos S, García-Garzón S, Lokhande M, Parra-Cid T.

Cell Immunol. 2011;269(2):104-14. doi: 10.1016/j.cellimm.2011.03.011. Epub 2011 Mar 17.

PMID:
21481848
7.

Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy.

Shin JH, Park HB, Choi K.

Immune Netw. 2016 Apr;16(2):134-9. doi: 10.4110/in.2016.16.2.134. Epub 2016 Apr 28.

8.

Maintenance of PD-1 on brain-resident memory CD8 T cells is antigen independent.

Shwetank, Abdelsamed HA, Frost EL, Schmitz HM, Mockus TE, Youngblood BA, Lukacher AE.

Immunol Cell Biol. 2017 Nov;95(10):953-959. doi: 10.1038/icb.2017.62. Epub 2017 Aug 22.

9.

Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice.

Roussey JA, Viglianti SP, Teitz-Tennenbaum S, Olszewski MA, Osterholzer JJ.

J Immunol. 2017 Nov 15;199(10):3535-3546. doi: 10.4049/jimmunol.1700840. Epub 2017 Oct 16.

10.

Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.

Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, Ibrani D, Koelle DM, Nghiem P.

Clin Cancer Res. 2013 Oct 1;19(19):5351-60. doi: 10.1158/1078-0432.CCR-13-0035. Epub 2013 Aug 6.

11.

Correlation of PD-1/PD-L1 Signaling Pathway with Treg/Th17 Imbalance from Asthmatic Children.

Xi X, Liu JM, Guo JY.

Int Arch Allergy Immunol. 2018;176(3-4):255-267. doi: 10.1159/000489338. Epub 2018 Jun 6.

PMID:
29874664
12.

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ.

J Immunother. 2017 Jan;40(1):31-35.

PMID:
27846054
14.

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.

Chen N, Fang W, Lin Z, Peng P, Wang J, Zhan J, Hong S, Huang J, Liu L, Sheng J, Zhou T, Chen Y, Zhang H, Zhang L.

Cancer Immunol Immunother. 2017 Sep;66(9):1175-1187. doi: 10.1007/s00262-017-2005-z. Epub 2017 Apr 27.

15.

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N.

Oncoimmunology. 2015 Oct 29;5(1):e1104448. eCollection 2016.

16.

CD32+ and PD-1+ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals.

Noto A, Procopio FA, Banga R, Suffiotti M, Corpataux JM, Cavassini M, Riva A, Fenwick C, Gottardo R, Perreau M, Pantaleo G.

J Virol. 2018 Sep 26;92(20). pii: e00901-18. doi: 10.1128/JVI.00901-18. Print 2018 Oct 15.

17.

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.

Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, Tei C, Arima N.

Leukemia. 2009 Feb;23(2):375-82. doi: 10.1038/leu.2008.272. Epub 2008 Oct 2.

PMID:
18830259
18.

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD.

Nature. 2006 Sep 21;443(7109):350-4. Epub 2006 Aug 20.

PMID:
16921384
19.

OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.

Buchan S, Manzo T, Flutter B, Rogel A, Edwards N, Zhang L, Sivakumaran S, Ghorashian S, Carpenter B, Bennett C, Freeman GJ, Sykes M, Croft M, Al-Shamkhani A, Chakraverty R.

J Immunol. 2015 Jan 1;194(1):125-133. doi: 10.4049/jimmunol.1401644. Epub 2014 Nov 17.

20.

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.

Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren N, Shinohara MM, Kluger HM, Bhatia S, Lundgren L, Cheever MA, Topalian SL, Nghiem P.

J Immunother Cancer. 2018 Nov 27;6(1):131. doi: 10.1186/s40425-018-0450-7.

Supplemental Content

Support Center